Adagio Therapeutics Inc, a coronavirus disease treatment developer, has filed Amendment No 1 to Form S-1 Registration Statement on August 2, 2021 with the U.S. Securities and Exchange Commission to announce terms for its IPO.
The company plans to raise $301 million by offering 17.7 million shares at a price range of $16 to $18. Assuming a successful IPO at the midpoint of the proposed price, the company expects a market capitalization of $2 billion.
The company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. They are developing our lead product candidate, ADG20, for the treatment and prevention of coronavirus disease 2019, or COVID-19, the disease caused by the virus SARS-CoV-2 and its variants.
The Waltham, Massachusetts-based company was founded in 2020 and plans to list on the Nasdaq Global Market under the symbol “ADGI.” Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities are underwriters of the IPO.
The company engages Cooley LLP as US Securities Counsel, and PricewaterhouseCoopers LLP as Independent Auditor.
#ipo #nasdaq #biotech #Adagio #coronavirus
Hexcellence Consulting has experienced IPO consulting team focus on listing in US Stock Market,
namely NYSE, Nasdaq and OTC Markets.
Should you interested to list your company in US Stock Market,
please contact us at [email protected]
